Screener / SEC EDGAR /CIK 0001109354 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Lab Instruments

Bruker Corp BRKR

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of BRKR's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Jun 26, 2017
Questions asked 7 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 7 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 4 of 4 closing letter

Half the closed reviews took 21 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-06-26 to 2017-07-17 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2017-07-17
Results discussion (MD&A)Income taxes
Operations · Income Tax Provision, page 47
SEC asked
We note the significant impact of the foreign tax rate differential on your effective tax rate on page 100. In future filings, revise to explain the impact of non-U.S. lower taxed jurisdictions on your effective tax rate, including a discussion of the primary taxing jurisdictions where your foreign earnings are derived, the location of tax holidays and the relevant statutory rates in those jurisdictions.
Rest of the question

Discuss any uncertainties relating to the income tax rates or benefits you currently receive in those jurisdictions. Refer to Item 303(a)(3) of Regulation S-K.

BRKR answered
We respectfully acknowledge the Staff’s comment and advise the Staff that in our future filings we will expand our disclosures included in Management’s Discussion and Analysis of Financial Condition and Results of Operations to explain, to the extent material, the impact of non-U.S. lower taxed jurisdictions on our effective tax rate.
Rest of the answer

Specifically, we will add appropriate discussion of the primary taxing jurisdictions where our foreign earnings are derived, the location of tax holidays, if any, and the relevant statutory rates in those jurisdictions, as well as any material uncertainties relating to the income tax rates or benefits we receive in those jurisdictions.

*******

If you would like to discuss the Company’s response, or any further questions that you may have, please do not hesitate to contact the undersigned at (978) 663-3660.

Read in the reply
In its next report

First report after the company's reply of Jun 30, 2017: 10-Q filed Aug 9, 2017 ↗, against the 10-Q filed May 10, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-07-17

Form 10-K for the Fiscal Year Ended December 31, 2015

2016-04-19 to 2016-04-28 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2016-04-28
RevenueNon-GAAP measuresResults discussion (MD&A)Liquidity and cash
Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked
You present various non-GAAP measures throughout your MD&A. For example, you discuss non-GAAP revenue and gross profit measures on page 42, a non-GAAP operating income measure on page 43, and free cash flow on page 40. Please revise future filings to include all of the disclosures required by Item 10(e)(1)(i) of Regulation S-K whenever you present non-GAAP financial measures.
BRKR answered
We respectfully acknowledge the Staff’s comment and advise the Staff that in our future filings, commencing with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, we will include all of the relevant disclosures required by Item 10(e)(1)(i) of Regulation S-K when we present non-GAAP financial measures.

*******

In responding to the comments of the Staff, the Company acknowledges that:

· the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

· Staff comments or the Company’s changes to disclosure in response to Staff comments do not
Rest of the answer

foreclose the Commission from taking any action with respect to the filing; and

· the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you would like to discuss any of the Company’s responses, or any further questions that you may have, please do not hesitate to contact the undersigned at (978) 663-3660.

Read in the reply
In its next report

First report after the company's reply of Apr 27, 2016: 10-Q filed May 6, 2016 ↗, against the 10-Q filed Nov 6, 2015 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2016-04-28

Form 10-K for the Fiscal Year Ended December 31, 2012

2013-06-04 to 2013-06-27 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2013-06-27
SegmentsRevenueResults discussion (MD&A)
Item 8. Financial Statements · Note 20. Business Segment Information, page 111
SEC asked (1)
We note the separate discussions of your Bruker MAT, Bruker BioSpin, and Bruker CALID operating segments in your Q1 2013 Earnings Presentation available on your website. It appears that the economic characteristics of these three operating segments may not be similar. Since you aggregate these segments, please provide us with your analysis under FASB ASC 280-10-50-11 on which you based your conclusion.
BRKR answered
The Company has aggregated the Bruker MAT, Bruker BioSpin and Bruker CALID operating segments (the “Operating Segments”) into the Bruker Scientific Instruments (“BSI”) reporting segment based upon the guidance within FASB ASC 280-10-50-11 (“ASC 280”), which states as follows:

“[T]wo or more operating segments may be aggregated into a single operating segment if aggregation is consistent with the objective and basic principles of this Subtopic, if the segments have similar economic characteristics, and if the segments are similar in all of the following areas:

a.
Rest of the answer

The nature of the products and services b. The nature of the production processes c. The type or class of customer for their products and services d. The methods used to distribute their products or provide their services e. If applicable, the nature of the regulatory environment, for example, banking, insurance, or public utilities”.

Principles of Aggregation

The Company believes that aggregating the Operating Segments into the BSI reporting segment is consistent with the objective and basic principles of ASC 280-10-50-11. Given the similarities amongst the Operating Segments, as discussed below, disclosure on an aggregated basis provides investors the relevant information that is meaningful to understanding the Company’s financial performance and future prospects. Accordingly, the Company has concluded that aggregation of the Operating Segments into a single BSI reporting segment is appropriate.

Economic Characteristics

ASC 280 specifically references comparable long-term average gross margin as an indicator of economic similarity. ASC 280 does not, however, define “comparable.” The following provides the Company’s historical gross profit margins for each of the Operating Segments:

ACTUAL

Gross Margin:

2010

2011

2012

Bruker BioSpin

[**]

%

Bruker CALID

Bruker MAT

Based on the historical gross margins noted above, the Operating Segments have had, and the Company believes each of the Operating Segments will continue to have, comparable long-term gross margins because of the similarities in the nature of products and services, production processes, methods to distribute the products and services and the types and classes of customers.

We are not aware of any external or internal factors that would change this relationship; in fact, we expect the gross margins of the Operating Segments to move closer together in the future as we implement additional Company initiatives (shared service centers and common ERP systems, among others) and this is reflected in our internal 2013 business plan and our internal 2014 and 2015 outlook.

In reviewing the internal 2013 business plan and our internal 2014 and 2015 outlook with respect to the individual Operating Segments’ gross margins, we found that the individual long-term gross margins are within (+/- 10%) of one another in the long-term, further supporting a determination that the Operating Segments have comparable long-term average gross margins.

Specific Aggregation Criteria

The following presents the Company’s conclusions on each of the aggregation criteria noted above:

a) The nature of products and services: All of the Operating Segments in the BSI reporting segment design, manufacture, and service analytical scientific instruments to address the needs of customers in life science research, pharmaceutical, biotechnology and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications. While the specific technologies and applications may be slightly different, there is substantial overlap and each of the Operating Segments sells to very similar customer bases (and often to the same customers). Each of the Operating Segments offer products and solutions that analyze and provide accurate information on the identity, quantity and key attributes of atomic and molecular structures. This analysis can be performed by magnets (Bruker BioSpin and Bruker CALID), mirrors (Bruker CALID) or X-ray tubes (Bruker MAT), but in the end the customers are identifying and analyzing the quantities and structural make-up of molecules and atoms using the Company’s technologically sophisticated analytical instruments. The various products offered are highly complementary and are often used by the same group within an organization to perform the research or commercial applications in which they are interested. The services provided in connection with these products are also similar and primarily include maintenance service agreements or fee for service arrangements, as well as accessory sales.

b) The nature of the production processes: The production processes are similar in nature mainly due to the similarities discussed in a) above. Each of the Operating Segments has similar products in that they include standardized products that are often conformed to customer specifications and involve similar integration processes during production. Moreover, the Operating Segments manufacture in the same regions, primarily Germany and Switzerland which account for over [**]% of products manufactured by each of the Operating Segments, with varying levels of production in the United States. The Operating

Segments also have very similar processes for procuring, handling, storing, testing and assembling and final testing the instrumentation. Each of the Operating Segments outsources non-core items such as power supplies, cabling and wiring, digitizer cards and sheet metal for its instruments. Additionally, each of the Operating Segments maintains the critical sub-assemblies and final testing processes in-house and has procedures to protect intellectual property and internal know-how. Support for these similarities can be seen when looking at typical average inventory levels, inventory turns, sourcing logistics and management, as well as overall working capital metrics.

c) The type and class of customer for products and services: The Operating Segments operate in the same core markets and share similar types and classes of customer for products and services. The largest class of customer within each of the Operating Segments is government and academia. The second largest class of customer within each of the Operating Segments is industrial and applied markets. In addition, the nature of the revenue mix within these markets is similar within each of the Operating Segments as each derives approximately 80% of its revenues from system sales, approximately 14% of its revenues from service related activities, and the remainder from system component upgrades and consumables. Finally, the Operating Segments share a common basis for competition as each competes on the basis of technical ability to meet customer specifications, product quality, reliable service and aftermarket support, and ability to develop new products and applications.

d) The method used to distribute products and services: The method used to distribute products and services is similar in nature for the Operating Segments. Distribution is typically direct once critical mass has been achieved. Prior to achieving sufficient volume levels to operate on a direct basis, third-party distributors are typically used for sales and service. In many cases the Operating Segments share sales and service offices around the world, including in Canada, the United Kingdom, Western Europe, Australia and China.

e) The nature of the regulatory environment: The Operating Segments are generally subject to the same local, federal and state regulatory environments.

Read in the reply
In its next report

First report after the company's reply of Jun 18, 2013: 10-Q filed Aug 8, 2013 ↗, against the 10-Q filed May 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Operations · Results of Operations, page 23
SEC asked (2)
We note from the Q1 2013 Earnings Presentation available on your website that lower than expected revenues in the quarter were due to, among other things, temporary operational issues. Please tell us more about these issues and quantify their impact on your revenues. Explain how you considered this in your disclosure in MD&A. Refer to Item 303(A) of Regulation S-K.
BRKR answered
The temporary operational issues noted in our Q1 2013 Earnings Presentation related to two items within our Bruker CALID group. The first issue relates to the implementation of a new ERP system in Germany. In conjunction with the implementation of this system, certain changes to manufacturing processes and order processing were required. The combination of the new ERP system and related process changes resulted in temporary operational and order execution inefficiencies that negatively impacted our Q1 2013 financial results.
Rest of the answer

The second issue was that during Q1 2013 there were a number of organizational and management changes within the CALID group, particularly in Asia, that temporarily impacted order execution and customer acceptance. The result of these temporary operational issues, in the aggregate, was a shortfall in revenues of approximately $[**] for Q1 2013 relative to the Company’s internal plan for the quarter.

Item 303(a)(3)(i) of Regulation S-K, states that registrants should “[d]escribe any unusual or infrequent events or transactions or any significant economic changes that materially affected the amount of reported income from continuing operations and, in each case, indicate the extent to which income was so affected. In addition, describe any other significant components of revenues or expenses that, in the registrant’s judgment, should be described in order to understand the registrant’s results of operations.” In addition, Item 303(a)(3)(ii) states that registrants should “[d]escribe any known trends or uncertainties that have had or that the registrant reasonably expects will have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations.” The impact of these temporary operational issues was not material to our Q1 2013 revenues reported within the BSI reporting segment. We also did not believe these items represented a trend or uncertainty that would have a material impact on our financial statements in future periods as we have implemented corrective measures to address these temporary operational issues and expect improvement in the remaining quarters of 2013. Management evaluated these factors and concluded that disclosure in MD&A was not required or necessary to promote an investor’s understanding of the Company and its results of operations.

Read in the reply
In its next report

First report after the company's reply of Jun 18, 2013: 10-Q filed Aug 8, 2013 ↗, against the 10-Q filed May 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Operations · Results of Operations, page 23
SEC asked (3)
Similarly, we note from the presentation that (i) Bruker MAT performance was impacted by weakness in global x-ray crystallography, and that within this group, Bruker Elemental and Bruker Nano Analytics divisions performed well due to the positive impact of new product introductions; (ii) Bruker BioSpin’s revenues declined due to installation delays caused by magnet rework issues and delayed availability of liquid
Rest of the question

helium; (iii) Bruker BioSpin’s operations were also impacted by the divestment of the French Power Electronics business and outsourcing Swiss electronics production; (iv) Bruker CALID had some temporary operational issues that impacted performance including a new ERP system and processes in Germany and organization and management changes; and (v) that BEST exited the iSCFL business. Please describe these issues to us in greater detail and quantify their impact on your segment results. Explain to us how you concluded that these issues should not be discussed in MD&A. Refer to Item 303(A) of Regulation S-K.

BRKR answered
Set forth below are the Company’s responses providing further descriptions of each of the items noted in the Staff’s comment, followed by an explanation of our analysis with respect to disclosure in MD&A included in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2013:

(i) Weakness in global x-ray crystallography at Bruker MAT, and that within this group, Bruker Elemental and Bruker Nano Analytics divisions performed well due to the positive impact of new product introductions: One of the performance factors in our Bruker MAT group in Q1 2013 was a weakness in our
Rest of the answer

x-ray crystallography product line as compared to same period last year, which negatively impacted our revenue in Q1 2013 in comparison to Q1 2012. This was driven by a reduction in academic funding in the United States and the cyclical nature of the demand for this product line. Offsetting the decrease were favorable results within our Bruker Elemental and Bruker Nano Analytics divisions due to the impact of multiple new product introductions over the last year. The combination of these factors represented a net increase in revenues of approximately $[**] and an increase in operating income of approximately $[**] in Q1 2013 as compared to Q1 2012 within the BSI reporting segment. Based on the foregoing, we believe the impact of these matters did not have a material impact on the Q1 2013 financial results, and therefore, did not require disclosure within MD&A.

(ii) Bruker BioSpin’s revenue shortfall related to installation delays caused by magnet rework issues and delayed availability of liquid helium: During Q1 2013 certain of our NMR magnets scheduled for delivery required rework to meet customer specifications. As a result, certain customer installations were delayed until subsequent quarters in 2013. The installation delays in Q1 2013 resulted in a shortfall in revenues of approximately $[**] and a shortfall in operating income of approximately $[**] within the BSI reporting segment, in each case relative to the Company’s internal plan for the quarter. Management expects the effect of these delays to be mitigated in subsequent quarters in 2013 as the installations are completed. Therefore we concluded that the installation delays did not require disclosure within MD&A.

With respect to the delayed availability of liquid helium, we noted as part of our Risk Factors in prior SEC filings, including in our Form 10-K for the year ended December 31, 2012, that there has been a global supply shortage for liquid helium which could lead to delays in system acceptances and ultimately revenue recognition in any particular period. The liquid helium shortage in Q1 2013 resulted in a shortfall in revenues of approximately $[**] and a shortfall in operating income of approximately $[**] within the BSI reporting segment, in each case relative to the Company’s internal plan for the quarter. Based on the foregoing, we believe the impact of this matter did not have a material impact on the Q1 2013 financial results, and therefore, did not require disclosure within MD&A. Although revenues may continue to fluctuate from quarter-to-quarter based on helium availability, we do not believe that any such supply shortages will have a material impact to our financial results for the full year.

(iii) Bruker BioSpin’s operations were also impacted by the divestment of the French Power Electronics business and outsourcing Swiss electronics production: As part of a continuing initiative to improve productivity, we began to divest certain loss-making or lower profitability businesses and outsource some of our non-core manufacturing activities. The divestiture of our French Power Electronics business and outsourcing of our Swiss electronics production during Q1 2013 was part of this initiative. The aggregate impact to Q1 2013 was a non-recurring charge of approximately $2.5 million within the BSI reporting segment. This amount was a component of the total restructuring costs incurred in Q1 2013 disclosed in our MD&A within “Other Charges” on page 25 of the Company’s Form 10-Q for the period ended March 31, 2013. These outsourcing initiatives had no impact on revenue due to the timing of execution of these transactions.

(iv) Bruker CALID had some temporary operational issues that impacted performance including a new ERP system and processes in Germany and organization and management changes: The temporary operational issues were described in our response to Comment #2 above. The impact to Q1 2013 results represented a shortfall in revenues of approximately $[**] and a shortfall in operating income of approximately $[**] within the BSI reporting segment relative to the Company’s internal plan for the quarter. Based on the foregoing, we believe the impact of these matters did not have a material impact on the Q1 2013 financial results. Additionally, we expect these temporary operational issues to be resolved in subsequent quarters in 2013; therefore, we do not anticipate that they will have a significant impact on our financial performance for the full year. Accordingly, we concluded that these issues did not require disclosure within MD&A.

(v) BEST exited the iSCFL business: As part of the initiative to improve productivity noted in item (iii) above, our Bruker Energy & Supercon Technologies division (“BEST”) exited the inductive Superconducting Fault Current Limiter (“iSFCL”) business. This process started in Q4 2012 and was completed in Q1 2013. The iSFCL business was not a significant business for the BEST division. The impact to Q1 2013 results represented a decrease in revenues of approximately $0.4 million and an increase in operating income of approximately $0.3 million compared to Q1 2012 within the BEST reporting segment. Based on the foregoing, we believe the impact of this matter did not have a material impact on the Q1 2013 financial results, and therefore, did not require disclosure within MD&A.

In accordance with Item 303(A) of Regulation S-K, we reviewed each of the above matters to determine if these items were material in nature or represented a known trend or uncertainty that would be required to be included in our MD&A disclosures. Based on the non-recurring nature of the above matters and the financial impact of these amounts on segment results, we believe we have made appropriate disclosure within MD&A to promote an investor’s understanding of the Company and its results of operations for the period ended March 31, 2013.

*******

In responding to the comments of the Staff, the Company acknowledges that:

· the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

· Staff comments or the Company’s changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

· the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you would like to discuss any of the Company’s responses, or any further questions that you may have, please do not hesitate to contact the undersigned at (978) 663-3660.

Respectfully,

/s/ CHARLES F. WAGNER, JR.

Charles F. Wagner, Jr.

Executive Vice President and Chief Financial Officer cc: Kate Tillan, Assistant Chief Accountant, Securities and Exchange Commission

Read in the reply
In its next report

First report after the company's reply of Jun 18, 2013: 10-Q filed Aug 8, 2013 ↗, against the 10-Q filed May 9, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2013-06-27

Form 10-K for the fiscal year ended December 31, 2011

2012-07-05 to 2012-07-24 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2012-07-24
RevenueResults discussion (MD&A)Liquidity and cashChinaControls
Operations, page 39 · Liquidity and Capital Resources, page 59
SEC asked (1)
We note that over 80% of your revenue is generated from sales to customers in foreign countries. In future filings, if material to an understanding of your liquidity, please disclose the amount of cash and cash equivalents held by foreign subsidiaries. As relevant, please also describe the potential tax impact that could arise from repatriation of undistributed earnings of your foreign subsidiaries.
Rest of the question

We refer you to Item 303(a)(1) of Regulation S-K and Section IV of SEC Release 33-8350.

BRKR answered
In future filings, to the extent such information would be material to an understanding of our liquidity, we confirm that we will expand our discussion within Liquidity and Capital Resources to clarify the amount of cash and cash equivalents held by our foreign subsidiaries. We will also provide, as relevant, a description of the potential tax impact that could arise from repatriation of the undistributed earnings of our foreign subsidiaries.

We supplementally advise the Staff that, beginning with the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2012, we
Rest of the answer

expect to include in our discussion of Liquidity and Capital Resources disclosure to the effect set forth below, updated as appropriate to reflect results for the relevant reporting period.

At December 31, 2011 and 2010, we had $212.4 million and $202.6 million, respectively, of foreign cash and cash equivalents, most significantly in Germany and Switzerland, compared to a total amount of cash and cash equivalents at December 31, 2011 and 2010 of $246.0 million and $230.4 million, respectively. If the cash and cash equivalents held by our foreign subsidiaries are needed to fund operations in the U.S., or we otherwise elect to repatriate the unremitted earnings of our foreign subsidiaries in the form of dividends or otherwise, or if the shares of the subsidiaries were sold or transferred, we would likely be subject to additional U.S. income taxes, net of the impact of any available foreign tax credits, which could result in a higher effective tax rate in the future. However, since we have significant current investment plans outside the U.S., it is our current intent to permanently reinvest unremitted earnings in our foreign subsidiaries. Further, based on our current plans and anticipated cash needs to fund our U.S. operations, we do not foresee a need to repatriate earnings of our foreign subsidiaries.

Read in the reply
In its next report

First report after the company's reply of Jul 19, 2012: 10-Q filed Aug 9, 2012 ↗, against the 10-Q filed May 9, 2012 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 9A Controls and Procedures, page 113 · Changes in Control over Financial Reporting, page 113
SEC asked (2)
Please reference the disclosure on page 17 related to the internal investigation and compliance matters. We see that in response to the FCPA investigation, you implemented an enhanced FCPA compliance program and strengthened the financial controls and oversight at subsidiaries operating in China and Hong Kong.
Rest of the question

Please tell us how you considered whether this represented a change in controls over financial reporting that should be disclosed under Item 9A. Please also tell us how you considered these matters in your assessment of internal control over financial reporting and disclosure controls and procedures at December 31, 2011.

BRKR answered
Item 9A of Form 10-K requires the Company to disclose any change in internal control over financial reporting that occurred during the fourth quarter of the fiscal year that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

In management’s judgment, the enhanced FCPA compliance program and strengthened financial controls and oversight implemented in our subsidiaries operating in China and Hong Kong did not constitute, either individually or in the aggregate, changes in internal controls over financial reporting
Rest of the answer

that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company made this determination based on management’s assessment of the nature and scope of the enhancements made to the Company’s existing programs and finance organization, which focused primarily on changes made to address specific process and personnel issues identified at the local level in our China and Hong Kong operations. Management also considered in its assessment of materiality the significance of these changes, taking into account the relative contribution of the China and Hong Kong operations to the Company’s consolidated financial results, the likely impact of these changes in the context of the Company’s overall internal control framework and the findings of management’s broader evaluation of the effectiveness of the Company’s internal control over financial reporting and disclosure controls and procedures at December 31, 2011. After consideration of these qualitative and quantitative factors, management determined that the changes implemented, as disclosed in our Annual Report on Form 10-K, did not materially affect, and were not reasonably likely to materially affect, the Company’s internal control over financial reporting.

In performing its assessment of the Company’s internal control over financial reporting and disclosure controls and procedures, management evaluated all controls that existed and were operating effectively at December 31, 2011. Specifically with respect to the FCPA compliance and local financial controls and oversight matters at our China and Hong Kong subsidiaries, management assessed the adequacy of its controls in the context of the Company’s broader control framework, taking into account relevant qualitative and quantitative factors. Management also noted that, although the FCPA related matters indicated that certain employees had violated the Company’s corporate policies and codes of conduct, the payments involved were properly recorded in the Company’s financial statements in the proper period, and were not deemed to be material to the financial position or results of operations of the Company in any reporting period. Management concluded that, although it was appropriate to implement enhancements to the Company’s existing FCPA compliance program and to make certain personnel changes, the Company’s internal control over financial reporting was effective at December 31, 2011 to provide reasonable assurance that such controls would not fail to prevent or detect a material misstatement of the Company’s consolidated financial results. Additionally, incorporating these considerations in its assessment, management concluded that the Company’s disclosure controls and procedures were effective at December 31, 2011 to ensure that the information required to be disclosed in the Company’s filings with the Commission is recorded, processed, summarized and timely reported.

*******

In responding to the comments of the Staff, the Company acknowledges that:

· the Company is responsible for the adequacy and accuracy of the disclosure in the filing;

· Staff comments or the Company’s changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

· the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

If you would like to discuss any of the Company’s responses, or any further questions that you may have, please do not hesitate to contact the undersigned at (978) 663-3660.

Respectfully,

/s/ CHARLES F. WAGNER

Charles F. Wagner

Executive Vice President and Chief Financial Officer cc: Gary Todd, Staff Accountant, Securities and Exchange Commission

Read in the reply
In its next report

First report after the company's reply of Jul 19, 2012: 10-Q filed Aug 9, 2012 ↗, against the 10-Q filed May 9, 2012 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2012-07-24

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 12 letters filed since 2012-07-05. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.